<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917318</url>
  </required_header>
  <id_info>
    <org_study_id>13-0207</org_study_id>
    <secondary_id>IIRP-1371</secondary_id>
    <nct_id>NCT01917318</nct_id>
  </id_info>
  <brief_title>Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether Iloperidone is effective in the treatment of
      some symptoms in patients with PTSD, particularly difficulty falling or staying asleep,
      trauma dreams and daytime irritability or outbursts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinician Administered PTSD Scale (CAPS) Part B and D score</measure>
    <time_frame>Data will be collected at randomization visit and at 1, 2, 4, 6, 8 weeks of treatment, during both treatment periods</time_frame>
    <description>Efficacy analysis will be based on data observed from randomization to 1, 2, 4, 6, 8 weeks of treatment and week 8 will serve as primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>Data will be collected at randomization visit and at 1, 2, 4, 6, 8 weeks of treatment during both treatment periods</time_frame>
    <description>Sleep will be measured by wrist actigraphy and sleep logs. Efficacy analysis will be based on data observed from randomization to 1, 2, 4, 6, 8 weeks of treatment and week 8 will serve as primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agitation</measure>
    <time_frame>Data will be collected at randomization visit and at 1, 2, 4, 6, 8 weeks of treatment during both treatment periods</time_frame>
    <description>Agitation will be measured by wrist actigraphy and CAPS item scores.Efficacy analysis will be based on data observed from randomization to 1, 2, 4, 6, 8 weeks of treatment and week 8 will serve as primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggression</measure>
    <time_frame>Data will be collected at randomization visit and at 1, 2, 4, 6, 8 weeks of treatment during both treatment periods</time_frame>
    <description>Aggression will be measured by the Modified Overt Aggression Scale. Efficacy analysis will be based on data observed from randomization to 1, 2, 4, 6, 8 weeks of treatment and week 8 will serve as primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal ideation and behavior</measure>
    <time_frame>Data will be collected at randomization visit and at 1, 2, 4, 6, 8 weeks of treatment during both treatment periods</time_frame>
    <description>Suicidal ideation and behavior will be measured by the Columbia Suicide Severity Rating Scale. Efficacy analysis will be based on data observed from randomization to 1, 2, 4, 6, 8 weeks of treatment and week 8 will serve as primary endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Iloperidone / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / Iloperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloperidone</intervention_name>
    <description>Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.
During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)</description>
    <arm_group_label>Iloperidone / Placebo</arm_group_label>
    <arm_group_label>Placebo / Iloperidone</arm_group_label>
    <other_name>Fanapt</other_name>
    <other_name>Fanapta</other_name>
    <other_name>Zomaril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During 8 weeks subjects will receive oral placebo</description>
    <arm_group_label>Iloperidone / Placebo</arm_group_label>
    <arm_group_label>Placebo / Iloperidone</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PTSD diagnosis

        Exclusion Criteria:

          -  Pregnancy

          -  Traumatic Brain Injury greater than mild

          -  Primary sleep disorder

          -  Caffeinism

          -  Active substance use disorder

          -  Active suicidal risk

          -  Antipsychotic medication, antibiotics, sedatives, some antihypertensive or
             antiarrhythmic medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Allen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine - Depression Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Depression Center; Clinical and Translational Research Center (CTRC)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ucdenver.edu/academics/colleges/medicalschool/departments/psychiatry/PatientCare/depressionctr/Pages/Welcome.aspx</url>
    <description>Depression Center - University of Colorado Denver</description>
  </link>
  <reference>
    <citation>Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009 Aug;63(8):1237-48. doi: 10.1111/j.1742-1241.2009.02142.x. Review.</citation>
    <PMID>19624791</PMID>
  </reference>
  <reference>
    <citation>David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety. 2006;23(8):489-91.</citation>
    <PMID>16845653</PMID>
  </reference>
  <reference>
    <citation>Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C; Veterans Affairs Cooperative Study No. 504 Group. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011 Aug 3;306(5):493-502. doi: 10.1001/jama.2011.1080.</citation>
    <PMID>21813427</PMID>
  </reference>
  <reference>
    <citation>Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. Psychophysiology. 2007 Jul;44(4):660-9. Epub 2007 May 22. Review.</citation>
    <PMID>17521374</PMID>
  </reference>
  <reference>
    <citation>Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003 Apr;23(2):193-6.</citation>
    <PMID>12640221</PMID>
  </reference>
  <reference>
    <citation>Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007 Apr 15;61(8):928-34. Epub 2006 Oct 25.</citation>
    <PMID>17069768</PMID>
  </reference>
  <reference>
    <citation>Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004 Dec;65(12):1601-6.</citation>
    <PMID>15641864</PMID>
  </reference>
  <reference>
    <citation>Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008 Mar 15;63(6):629-32. Epub 2007 Sep 14.</citation>
    <PMID>17868655</PMID>
  </reference>
  <reference>
    <citation>Wicklow A, Espie CA. Intrusive thoughts and their relationship to actigraphic measurement of sleep: towards a cognitive model of insomnia. Behav Res Ther. 2000 Jul;38(7):679-93.</citation>
    <PMID>10875190</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post traumatic stress disorder</keyword>
  <keyword>Treatment of post traumatic stress disorder</keyword>
  <keyword>Symptoms of arousal in post traumatic stress disorder</keyword>
  <keyword>Iloperidone in post traumatic stress disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 23, 2015</submitted>
    <returned>December 29, 2015</returned>
    <submitted>February 11, 2016</submitted>
    <returned>March 10, 2016</returned>
    <submitted>April 25, 2016</submitted>
    <returned>May 31, 2016</returned>
    <submitted>June 13, 2016</submitted>
    <returned>July 22, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

